Immix Biopharma, Inc. IMMX Share-Based Payment - Unrecognized Cost of Nonvested Awards
Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s share-based payment - unrecognized cost of nonvested awards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s share-based payment - unrecognized cost of nonvested awards?
- Immix Biopharma, Inc. (IMMX) reported share-based payment - unrecognized cost of nonvested awards of $3.98M in Q1 2026.
- How has Immix Biopharma, Inc.'s share-based payment - unrecognized cost of nonvested awards changed year-over-year?
- Immix Biopharma, Inc.'s share-based payment - unrecognized cost of nonvested awards increased by 66.4% year-over-year, from $2.39M to $3.98M.
- What does share-based payment - unrecognized cost of nonvested awards mean?
- This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.